WIRE — Biocon Q1 profit surged 348% to Rs. 141 crore as revenue rose 10% to Rs. 4,336 crore. Biosimilars and generics led growth, while EBITDA margin remained stable.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.